Related Experiment Video

Updated: Jan 20, 2026

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

687

A ROS-responsive polymeric prodrug nanosystem with self-amplified drug release for PSMA (-) prostate cancer specific

Yifan Wang1, Yanqiu Zhang2, Zhengxing Ru3

  • 1Department of Oncology, Yancheng First People's Hospital, Yancheng, 224005, China.

Journal of Nanobiotechnology
|August 28, 2019
PubMed
Abstract

Insights

Researchers developed a novel nanoplatform for prostate specific membrane antigen negative (PSMA (-)) prostate cancer. This targeted drug delivery system enhances therapeutic efficacy by amplifying drug release within cancer cells.

Area of Science:

  • Biomedical Engineering
  • Nanotechnology
  • Oncology

Background:

  • Limitations in current nano-drug delivery systems include poor tumor site accumulation and incomplete intracellular drug release.
  • Prostate specific membrane antigen negative (PSMA (-)) prostate cancer lacks effective targeted therapies due to the absence of suitable biomarkers.

Purpose of the Study:

  • To develop a novel nanoplatform for PSMA (-) prostate cancer therapy.
  • To enhance targeted drug delivery and overcome incomplete drug release within cancer cells.
  • To create a ROS-responsive, self-accelerating drug release system.

Main Methods:

  • Development of ATD-NPs comprising a PSMA (-) cancer-targeting peptide (DUP-PEG-DSPE), a ROS-sensitive doxorubicin (DOX) prodrug (P(L-TK-DOX)), and a ROS generation agent (α-tocopheryl succinate, α-TOS).
  • In vitro and in vivo evaluation of ATD-NPs for tumor targeting, cellular uptake, and drug release kinetics.
  • Assessment of antitumor activity and therapeutic efficacy in PSMA (-) prostate cancer models.

Main Results:

  • ATD-NPs specifically accumulated in tumor sites and were internalized by PSMA (-) cancer cells.
  • Intracellular ROS triggered the release of DOX and α-TOS, with α-TOS further amplifying ROS production and accelerating drug release.
  • The combination of active targeting and self-amplifying ROS-responsive drug release demonstrated significant antitumor activity in vitro and in vivo.

Conclusions:

  • The developed nanoplatform integrates active tumor targeting, self-amplified drug release, and good biocompatibility.
  • This technology shows promise for improving the therapeutic outcomes of PSMA (-) prostate cancer.
Keywords:
Intracellular ROS amplificationPMSAROS-responsiveSelf-accelerating

More Related Videos

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

12.6K
An Orthotopic Murine Model of Human Prostate Cancer Metastasis06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

35.8K

Related Concept Videos

Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
251
Prodrugs01:30

Prodrugs

Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
4.1K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.9K
Drugs Affecting Neurotransmitter Release or Uptake01:21

Drugs Affecting Neurotransmitter Release or Uptake

Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
BJT Amplifiers01:14

BJT Amplifiers

Bipolar Junction Transistors (BJTs) are pivotal components in amplifier circuits, functioning as voltage-controlled current sources in their active region. This characteristic allows them to efficiently control the collector current through variations in the base-emitter voltage. Essentially, BJTs amplify power due to their ability to take a weak input signal and output a much stronger signal.
In BJT amplifier configurations, particularly in common-emitter setups, the transistor's role...
963